MX2022006883A - Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. - Google Patents

Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario.

Info

Publication number
MX2022006883A
MX2022006883A MX2022006883A MX2022006883A MX2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A MX 2022006883 A MX2022006883 A MX 2022006883A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
relapsed
isatuximab
refractory multiple
treatment
Prior art date
Application number
MX2022006883A
Other languages
English (en)
Inventor
Marie- Laure Risse
Gaelle Asset
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of MX2022006883A publication Critical patent/MX2022006883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ceramic Products (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a métodos para tratar el mieloma múltiple (como el mieloma múltiple refractario o el mieloma múltiple recidivante y refractario) en un individuo que recibió de una a tres terapias anteriores (o líneas de terapia anteriores) para el mieloma múltiple. Los métodos comprenden la administración al individuo de un anticuerpo anti-CD30, carfilzomib y dexametasona.
MX2022006883A 2019-12-06 2020-12-04 Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. MX2022006883A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US202063094833P 2020-10-21 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
MX2022006883A true MX2022006883A (es) 2022-11-08

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006883A MX2022006883A (es) 2019-12-06 2020-12-04 Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario.

Country Status (13)

Country Link
US (1) US20210171653A1 (es)
EP (1) EP4069740A1 (es)
JP (1) JP2023505219A (es)
KR (1) KR20220159948A (es)
CN (1) CN115698065A (es)
AU (1) AU2020398655A1 (es)
BR (1) BR112022010907A2 (es)
CA (1) CA3164026A1 (es)
CO (1) CO2022009433A2 (es)
IL (1) IL293615A (es)
MX (1) MX2022006883A (es)
TW (1) TW202133880A (es)
WO (1) WO2021113754A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SG10201707464SA (en) * 2013-03-13 2017-10-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
EP3063173B1 (en) * 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
CA3079242A1 (en) * 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
IL293615A (en) 2022-08-01
CA3164026A1 (en) 2021-06-10
WO2021113754A1 (en) 2021-06-10
TW202133880A (zh) 2021-09-16
US20210171653A1 (en) 2021-06-10
CO2022009433A2 (es) 2022-07-29
EP4069740A1 (en) 2022-10-12
JP2023505219A (ja) 2023-02-08
AU2020398655A1 (en) 2022-07-28
KR20220159948A (ko) 2022-12-05
BR112022010907A2 (pt) 2022-10-18
CN115698065A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
NZ769968A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12020552229A1 (en) Il-11ra antibodies
MX2021009079A (es) Metodos para tratar el mieloma multiple.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021006954A (es) Terapia combinada contra el virus de la hepatitis b (vhb).
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
TW201613975A (en) Methods for treating multiple myeloma
MX2019013862A (es) Terapia de combinacion.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.